ShareholdingJul 31, 2026, 04:21 PM
VivoSim Labs Registers 9.41M Shares for Resale by Selling Stockholder
AI Summary
VivoSim Labs, Inc. filed an S-1 registration statement to register 9,411,766 shares of common stock for resale by Armistice Capital Master Fund Ltd. These shares are issuable upon the exercise of pre-funded and common warrants. The company recently shifted its business model from clinical stage biotechnology to providing pharmaceutical and biotechnology services using 3D human tissue models, and received a $5.0 million milestone payment in July 2026.
Key Highlights
- VivoSim Labs registered 9,411,766 shares of common stock for resale.
- Shares include 4,705,883 Pre-Funded Warrant Shares and 4,705,883 Common Warrant Shares.
- The selling stockholder is Armistice Capital Master Fund Ltd.
- Common Warrants have an exercise price of $0.85 per share.
- Company transitioned from clinical stage biotech to pharmaceutical services.
- Received $5.0 million milestone payment in July 2026 for FXR program.
- Common Stock listed on Nasdaq Capital Market under symbol "VIVS".
Price Impact
More from VIVS